DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Clinical trials for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Targeting CAR t therapy aims to outperform standard treatment in lymphoma
Disease control Recruiting nowThis study tests a new cell therapy called ronde-cel that targets two proteins (CD19 and CD20) on lymphoma cells, compared to standard CAR T-cell therapy that targets only one. About 400 adults with large B-cell lymphoma that came back or didn't respond to first treatment will ta…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
New pill targets virus-driven lymphoma in patients out of options
Disease control Recruiting nowThis early-phase study tests an experimental daily pill, VK-2019, in about 30 adults whose EBV-positive diffuse large B-cell lymphoma has returned or not responded after at least two prior treatments. The main goal is to find the safest dose by giving three different dose levels …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New Dual-Target CAR t therapy aims to outsmart tough blood cancers
Disease control Recruiting nowThis early-phase study tests a new cell therapy called GF-CART01 in 18 adults aged 18-70 with B-cell blood cancers (like lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two markers (CD20 and …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New combo aims to boost CAR T-Cell success in lymphoma patients
Disease control Recruiting nowThis early-stage study tests a combination of two drugs, CC-99282 and rituximab, in people with non-Hodgkin lymphoma whose cancer did not respond well to CAR T-cell therapy. The goal is to find a safe dose and see if the combo can help control the cancer. About 18 adults with cer…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated May 11, 2026 20:39 UTC